Bicara Therapeutics (BCAX) Current Leases (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Current Leases data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 92.89% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 92.89% YoY), and the FY2025 full-year result was $1.1 million, up 84.02% from the prior year.
• Current Leases for Q1 2026 stood at $1.1 million, up from $1.1 million in the prior quarter.
• Across five years, Current Leases topped out at $1.1 million in Q1 2026 and bottomed at $285000.0 in Q4 2023.
• The 4-year median for Current Leases is $840500.0 (2024), against an average of $777125.0.
• Peak annual rise in Current Leases reached 255.52% in 2025, while the deepest fall reached 84.02% in 2025.
• A 4-year view of Current Leases shows it stood at $285000.0 in 2023, then surged by 112.98% to $607000.0 in 2024, then surged by 84.02% to $1.1 million in 2025, then rose by 2.06% to $1.1 million in 2026.
• The last three Current Leases figures came in at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.

Peer Comparison